GlaxoSmithKline, LLC.
$242.1M 341,439 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
E.R. Squibb & Sons, L.L.C.
E.R. Squibb & Sons, L.L.C. reported $251,493,412.98 across General Payments, Research, and Ownership to 236,558 physicians and teaching hospitals across 241,583 transactions.
- $251.5M Top 1% payer
- All-tracks total
- 241,583 Top 1% volume
- Transactions
- 236,558 Top 1% reach
- Recipients
- −$149.0K
- General Payments vs PY2023
E.R. Squibb & Sons, L.L.C. reported $251,493,412.98 across all CMS Open Payments tracks (General + Research + Ownership) to 236,558 physicians and teaching hospitals in Program Year 2024 - ranking #12 of 1,925 reporting manufacturers (1.8% of the all-tracks industry total); General Payments alone were $31,001,339.34, averaging $1.1K per recipient.
How E.R. Squibb & Sons, L.L.C.'s $251.5M all-tracks total breaks down
E.R. Squibb & Sons, L.L.C.'s payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
A
100/100
Total payments
A
100/100
Transaction volume
A
100/100
Physician reach
A
100/100
Payment type diversity
A
100/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer e-r-squibb-sons-l-l-c E.R. Squibb & Sons, L.L.C.
$251.5M · #12/1,925 · 1.8% industry · PY2024
- TOT $251.5M
- RANK #12
- SHARE 1.8%
- TXN 241,583
- RCP 236,558
- CAT 12
- GEN $31.0M
- ΔGEN −$149.0K
- TOP1 0.9%
- PY 2024
Volume peers
Nearest volume peer: GlaxoSmithKline, LLC. ($242.1M)
E.R. Squibb & Sons, L.L.C. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
E.R. Squibb & Sons, L.L.C.'s CMS-reported General Payments decreased by $149.0K (−0.5%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: E.R. SQUIBB & SONS, L.L.C.PY2023: E.R. SQUIBB & SONS, L.L.C.PY2024: E.R. Squibb & Sons, L.L.C.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $31,150,362.29
- PY2024
- $31,001,339.34
What the Data Shows for E.R. Squibb & Sons, L.L.C.
The all-tracks total above combines three CMS reporting categories - General Payments, Research Payments, and Ownership/Investment interests - not one undifferentiated figure. For E.R. Squibb & Sons, L.L.C., that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. CMS publishes each Program Year's data roughly 12 months after the reporting period ends, so this reflects the most recently released cycle; see our methodology for how the tracks are standardized and compared across companies.
The 12-category breakdown below covers general payments only (see our methodology for how research and ownership payments are reported separately). The largest general-payment category is "Compensation for Services Other Than Consulting" at $12.9M, accounting for 41.5% of this company's General Payments and 4,162 transactions.
General Payment Breakdown by Type
E.R. Squibb & Sons, L.L.C. made 12 types of general payments. "Compensation for Services Other Than Consulting" is the largest category at $12.9M, 41.5% of General Payments.
E.R. Squibb & Sons, L.L.C. reports 12 general-payment categories - the top three are Compensation for Services Other Than Consulting (41.5%), Consulting Fee (24.4%), and Food and Beverage (18.4%). The remaining 9 categories make up 15.6% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
Category breadth matters here: E.R. Squibb & Sons, L.L.C. files across 12 named CMS general-payment types in Program Year 2024, versus manufacturers that report a single dominant category. The chart and table below enumerate every type with an amount above zero for this company.
How E.R. Squibb & Sons, L.L.C. divides its payments
How the reported total splits across payment categories
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Compensation for Services Other Than Consulting | $12.9M | 4,162 | 41.5% |
| Consulting Fee | $7.6M | 3,214 | 24.4% |
| Food and Beverage | $5.7M | 220,026 | 18.4% |
| Travel and Lodging | $2.6M | 6,446 | 8.3% |
| Space Rental or Facility Fees | $791.3K | 253 | 2.6% |
| Royalty or License | $501.6K | 11 | 1.6% |
| Grant | $499.9K | 31 | 1.6% |
| Education | $242.7K | 2,338 | 0.8% |
| Charitable Contribution | $101.5K | 2 | 0.3% |
| Compensation for Faculty or Speaker (Medical Education) | $74.6K | 48 | 0.2% |
| Honoraria | $63.4K | 18 | 0.2% |
| Gift | $5.3K | 9 | 0.0% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $953,371.92 (3.1%) of $31,001,339.34 in this company's General Payments records across 63,973 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for E.R. Squibb & Sons, L.L.C.
The five named recipients with the highest reported General Payments from this company
- 1
University Of Washington Med Ctr
$265,000.00 across 4 reported transactions
- 2
Univ Of Mi Hospitals & Hlth Ctrs
$199,936.54 across 8 reported transactions
- 3
Ronan Kelly
$197,554.64 across 84 reported transactions
- 4
Rush University Medical Center
$155,500.00 across 4 reported transactions
- 5
Matthew Martinez
$135,380.74 across 122 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
E.R. Squibb & Sons, L.L.C. ranks #12 of 1,925 by total payments (top 1% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #1,827 of 1,838 by HHI (bottom 1% least concentrated), a wider distribution than most similarly sized payers.
View all 12 companies in this HHI neighborhood as a list
- Kestra Medical Technology Services, Inc. : $515.4K total payments, HHI 17
- Aytu BioPharma, Inc. : $14.7K total payments, HHI 17
- Lilly USA, LLC : $46.6M total payments, HHI 16
- 180 Medical, Inc. : $86.9K total payments, HHI 13
- Janssen Biotech, Inc. : $30.9M total payments, HHI 13
- Amphastar Pharmaceuticals, Inc. : $41.3K total payments, HHI 13
- E.R. Squibb & Sons, L.L.C. (this company) : $31.0M total payments, HHI 12
- Aspira Women's Health Inc : $74.7K total payments, HHI 12
- Corium, LLC : $1.7M total payments, HHI 11
- Novo Nordisk Inc : $25.5M total payments, HHI 9
- Beta Bionics, Inc. : $243.6K total payments, HHI 8
- Innovation Technologies Inc : $205.0K total payments, HHI 8
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as E.R. Squibb & Sons, L.L.C.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about E.R. Squibb & Sons, L.L.C..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with E.R. Squibb & Sons, L.L.C..
Showing 6 of 1,924 companies with CMS-reported payment data.
BioNTech SE
$204.8M 179 recipients
Compare payment profiles
Takeda Pharmaceuticals U.S.A., Inc.
$199.9M 172,058 recipients
Compare payment profiles
Medtronic, Inc.
$189.9M 342,681 recipients
Compare payment profiles
Amgen Inc.
$343.0M 474,864 recipients
Compare payment profiles
Janssen Research & Development, LLC
$345.1M 1,588 recipients
Compare payment profiles
Put this to use
E.R. Squibb & Sons, L.L.C. ranks #12 of 1,925 by all-tracks total payments, led by "Compensation for Services Other Than Consulting".
- See where E.R. Squibb & Sons, L.L.C. sits among every top spender on the full leaderboard. Top 100 by total payments
- Compare "Compensation for Services Other Than Consulting" spend across every manufacturer, not just E.R. Squibb & Sons, L.L.C.. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.